Topic: Triphendiol clinical trial application filed
An application for a clinical trial has been filed for Triphendiol, which has orphan drug status, to be used as a chemosensitizing agent with gemcitabine.
There is a lot to be hopeful for here, some of the highlights:
-looks like the trial would be open to patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers (many trials exclude those with metastases)
-exhibits high selectivity, little effect on non-tumor cells and no observable toxicity in animals at therapeutically effective doses
-in human studies conducted in Australia, no adverse events or side effects have been reported
Read the full press release here: